David Zaccardelli Sells 2,400 Shares of Verona Pharma plc (NASDAQ:VRNA) Stock

Verona Pharma plc (NASDAQ:VRNA) CEO David Zaccardelli sold 2,400 shares of the firm’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $5.00, for a total value of $12,000.00. Following the transaction, the chief executive officer now directly owns 15,202,352 shares in the company, valued at $76,011,760. This trade represents a 0.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

David Zaccardelli also recently made the following trade(s):

• On Monday, November 4th, David Zaccardelli sold 94,144 shares of Verona Pharma stock. The shares were sold at an average price of $4.39, for a total value of $413,292.16.
• On Friday, November 1st, David Zaccardelli sold 46,888 shares of Verona Pharma stock. The stock was sold at an average price of $4.38, for a total value of $205,369.44.
• On Friday, October 25th, David Zaccardelli sold 4,800 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total value of $21,024.00.
• On Wednesday, October 23rd, David Zaccardelli sold 16 shares of Verona Pharma stock. The stock was sold at an average price of $4.38, for a total transaction of $70.08.
• On Monday, October 21st, David Zaccardelli sold 110,456 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total transaction of $483,797.28.
• On Friday, October 18th, David Zaccardelli sold 245,784 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total transaction of $1,076,533.92.

Verona Pharma Stock Performance

Shares of Verona Pharma stock opened at $35.37 on Friday. The business has a fifty day simple moving average of $32.42 and a two-hundred day simple moving average of $23.40. The company has a debt-to-equity ratio of 0.93, a current ratio of 13.03 and a quick ratio of 12.88. Verona Pharma plc has a 12 month low of $11.39 and a 12 month high of $40.13.

Verona Pharma (NASDAQ:VRNA) last issued its quarterly earnings results on Monday, November 4th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.12). The company had revenue of $5.62 million for the quarter, compared to the consensus estimate of $2.31 million. During the same period in the prior year, the business posted ($0.18) earnings per share. On average, research analysts expect that Verona Pharma plc will post -2.11 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on VRNA shares. Canaccord Genuity Group raised their target price on Verona Pharma from $37.00 to $44.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. Wells Fargo & Company boosted their target price on Verona Pharma from $50.00 to $64.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Truist Financial raised their price target on Verona Pharma from $38.00 to $44.00 and gave the stock a “buy” rating in a research note on Wednesday, October 9th. Finally, HC Wainwright boosted their price objective on shares of Verona Pharma from $36.00 to $42.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $43.83.

Institutional Trading of Verona Pharma

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. CWM LLC bought a new stake in Verona Pharma in the second quarter worth $29,000. EMC Capital Management purchased a new stake in Verona Pharma during the 2nd quarter valued at about $38,000. GAMMA Investing LLC grew its position in Verona Pharma by 70.6% during the 3rd quarter. GAMMA Investing LLC now owns 1,336 shares of the company’s stock valued at $38,000 after purchasing an additional 553 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Verona Pharma by 25.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,610 shares of the company’s stock valued at $75,000 after purchasing an additional 529 shares in the last quarter. Finally, Legato Capital Management LLC purchased a new position in Verona Pharma in the second quarter worth about $154,000. Hedge funds and other institutional investors own 85.88% of the company’s stock.

Verona Pharma Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.